Biogen, in partnership with Isis Pharmaceuticals, has announced a new Phase 2 clinical trial, called EMBRACE.
EMBRACE is a multi-center, Phase 2 clinical study evaluating the safety and exploratory efficacy of the investigational drug, ISIS-SMNRx, (ISIS 396443) in patients with infantile or childhood-onset Spinal Muscular Atrophy (SMA). The study is a double-blind, randomized, sham-procedure controlled study, designed to examine the safety & exploratory efficacy of ISIS-SMNRx in approximately 20 patients with SMA over a 14 month period.
Please see the EMBRACE Q&A for details on enrollment criteria, or contact one of the participating trial centers for more information.
Ongoing Clinical Trials
EMBRACE is the fourth ongoing trial testing ISIS-SMNRx. The others are:
- ENDEAR, a Phase 3 clinical trial testing infants with SMA type I
- CHERISH, a Phase 3 clinical trial testing children age 2-12, with onset of symptoms at age six months or later
- NURTURE, a Phase 2 clinical trial testing very young infants who are genetically predisposed to SMA but not yet showing symptoms